Key Highlights
- Sudo Biosciences completes a second close of its Series B financing, raising $30 million from new investors including DDF, Leaps by Bayer, and UPMC Enterprises.
- Total funding for this round reaches $147 million, with overall funding hitting $188 million since 2020.
- Funds will advance two investigational TYK2 candidates into the clinic in 2024, targeting multiple sclerosis, Alzheimer’s, ALS, and immune-mediated dermatologic diseases.
Source: Business Wire
Notable Quotes
- “We are pleased to welcome these new investors…meaningful for Sudo as we advance our precision TYK2 inhibitors into the clinic.” – Scott Byrd, CEO at Sudo Biosciences
- “We are happy to partner with Sudo…into Alzheimer’s and ALS.” – Jonathan Behr, Partner at SV Health Investors
- “Sudo Biosciences is at the forefront of developing groundbreaking therapies…improving the lives of many patients.” – Juergen Eckhardt, Head at Leaps by Bayer
SoHC's Take
The strategic infusion of $30 million into Sudo Biosciences’ Series B funding round from prominent investors like DDF, Leaps by Bayer, and UPMC Enterprises marks a significant milestone in the biopharmaceutical industry, especially in the precision medicine space. This round not only highlights the growing confidence in Sudo’s innovative TYK2 inhibitors but also underscores the potential impact these treatments could have on autoimmune and neurodegenerative diseases. With a total of $188 million raised since its inception, Sudo is poised to accelerate the development of its promising pipeline, potentially offering new hope for patients with conditions like multiple sclerosis, Alzheimer’s, and ALS. This development reflects a broader trend towards targeted therapies, with investors increasingly backing companies that show promise in addressing unmet medical needs through precision medicine.
